EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A review of conjugation technologies for antibody drug conjugates

Qirui Fan, Hu Chen, Guoguang Wei, Ding Wei, Zekun Wang, Lin Zhang, Jun Wang, Marie Zhu

Antibody Therapeutics · 28.03.2025 · 8 (2) · 157-170

DOI: 10.1093/abt/tbaf010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antibody Therapeutics, online erschienen am 17.04.2025. Verfasst von Qirui Fan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Discovery & Development, WuXi XDC Co., Ltd, 520 Fute North Road, Pilot Free Trade Zone, Pudong New Area, Shanghai, 200131, China. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: WuXi XDC Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody–drug conjugates (ADCs) have gained significant attention in biotherapeutics after several years of steady development. Among the multiple factors influencing ADC design, the conjugation method is one of the most critical parameters. This review classifies conjugation strategies into three categories: non-specific, site-specific but non-selective, and fully site-specific and selective methods. The characteristics; advantages and disadvantages; chemistry, manufacturing, and controls (CMC) potential; and clinical status of each conjugation strategy are discussed in detail. The site-specific and selective methods will yield more homogeneous ADC, which may influence the stability and pharmacokinetics (PK) profile of the ADC and then influence the final therapeutic outcome. Additionally, the review also explores challenges and future directions for developing novel conjugation strategies. This review presents the most prevalent conjugation techniques, providing a valuable resource for researchers in selecting conjugation technologies and advancing ADC development.

Schlagwörter

Stichwörter der Autor:innen

affinity peptide conjugationantibody–drug conjugate (ADC)cysteine conjugationenzymatic-tag conjugationglycan remodeling conjugationlysine conjugationnon-canonical amino acids (ncAAs) conjugation

Autor:innen und Institutionen

  • Department of Discovery & Development, WuXi XDC Co., Ltd, 520 Fute North Road, Pilot Free Trade Zone, Pudong New Area, Shanghai, 200131, China.

Förderung

  • WuXi XDC Co., Ltd.

Zitieren

APA

Fan, Q., Chen, H., Wei, G., Wei, D., Wang, Z., Zhang, L., Wang, J., & Zhu, M. (2025). A review of conjugation technologies for antibody drug conjugates. Antibody Therapeutics, 8(2), 157-170. https://doi.org/10.1093/abt/tbaf010

Vancouver

Fan Q, Chen H, Wei G, Wei D, Wang Z, Zhang L, et al. A review of conjugation technologies for antibody drug conjugates. Antibody Therapeutics. 2025;8(2):157-170. doi:10.1093/abt/tbaf010

BibTeX
@article{Fan2025,
  author = {Fan, Qirui and Chen, Hu and Wei, Guoguang and Wei, Ding and Wang, Zekun and Zhang, Lin and Wang, Jun and Zhu, Marie},
  title = {A review of conjugation technologies for antibody drug conjugates},
  journal = {Antibody Therapeutics},
  year = {2025},
  volume = {8},
  number = {2},
  pages = {157--170},
  doi = {10.1093/abt/tbaf010}
}
Kostenlos starten →